Qureshi Adnan I, Suri M Fareed K, Sung Gene Y, Straw Robert N, Yahia Abutaher M, Saad Mustafa, Guterman Lee R, Hopkins L Nelson
Department of Neurosurgery and Toshiba Stroke Research Center, University at Buffalo, The State University of New York, Buffalo, New York 14209-1194, USA.
Neurosurgery. 2002 Apr;50(4):749-55; discussion 755-6. doi: 10.1097/00006123-200204000-00012.
Abnormal serum sodium levels (hyponatremia and hypernatremia) are frequently observed during the acute period after aneurysmal subarachnoid hemorrhage (SAH) and may worsen cerebral edema and mass effect. We performed this study to determine the prognostic significance of serum sodium concentration abnormalities.
We analyzed prospectively collected data for the placebo treatment group in a clinical trial conducted at 54 neurosurgical centers in North America. The presence of hypernatremia (serum sodium concentration of >145 mmol/L) and hyponatremia (serum sodium concentration of <135 mmol/L) was determined with serum sodium measurements obtained at admission and 3, 6, and 9 days after SAH. The effects of hypernatremia and hyponatremia on the risk of symptomatic vasospasm and on 3-month outcomes were analyzed after adjustment for the following potential confounding factors: age, sex, preexisting hypertension, admission Glasgow Coma Scale score, initial mean arterial pressure, subarachnoid clot thickness, intraventricular blood or intraparenchymal hematoma, ventricular dilation, and aneurysm size and location.
Of 298 patients in the analysis, 58 (19%) developed hypernatremia and 88 (30%) developed hyponatremia. Hypernatremia was significantly associated with poor outcomes (odds ratio, 2.7; 95% confidence interval, 1.2-6.1). A positive correlation was observed between the highest sodium values recorded and Glasgow Outcome Scale scores at 3 months (P < 0.0001 by analysis of variance). Hyponatremia was not associated with 3-month outcomes (odds ratio, 1.9; 95% confidence interval, 0.9-4.3). Neither hypernatremia nor hyponatremia was associated with the risk of symptomatic vasospasm.
Hyponatremia seems to be more common than hypernatremia after SAH. However, hypernatremia after SAH is independently associated with poor outcomes, and this association is independent of previously identified outcome predictors, including age and admission Glasgow Coma Scale scores. Further studies are needed to define the underlying mechanism of this association.
在动脉瘤性蛛网膜下腔出血(SAH)后的急性期,经常观察到血清钠水平异常(低钠血症和高钠血症),这可能会加重脑水肿和占位效应。我们进行这项研究以确定血清钠浓度异常的预后意义。
我们分析了在北美54个神经外科中心进行的一项临床试验中前瞻性收集的安慰剂治疗组数据。通过在SAH入院时以及SAH后3天、6天和9天测得的血清钠水平来确定高钠血症(血清钠浓度>145 mmol/L)和低钠血症(血清钠浓度<135 mmol/L)的存在情况。在对以下潜在混杂因素进行校正后,分析高钠血症和低钠血症对有症状血管痉挛风险以及3个月预后的影响:年龄、性别、既往高血压病史、入院时格拉斯哥昏迷量表评分、初始平均动脉压、蛛网膜下腔血凝块厚度、脑室内出血或脑实质内血肿、脑室扩张以及动脉瘤大小和位置。
在分析的298例患者中,58例(19%)发生高钠血症,88例(30%)发生低钠血症。高钠血症与不良预后显著相关(比值比,2.7;95%置信区间,1.2 - 6.1)。在记录的最高钠值与3个月时的格拉斯哥预后量表评分之间观察到正相关(方差分析,P < 0.0001)。低钠血症与3个月预后无关(比值比,1.9;95%置信区间,0.9 - 4.3)。高钠血症和低钠血症均与有症状血管痉挛的风险无关。
SAH后低钠血症似乎比高钠血症更常见。然而,SAH后的高钠血症与不良预后独立相关,并且这种关联独立于先前确定的预后预测因素,包括年龄和入院时格拉斯哥昏迷量表评分。需要进一步研究来确定这种关联的潜在机制。